Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (41-50 of 190) with videos related to

Pageof 19
Sort By:
Pharmaceutical Statistics|April 11, 2023
Generalized phase I-II designs to increase long term therapeutic success ratePeter F Thall, Yong Zang, Ying Yuan
Journal of the American Statistical Association|May 18, 2022
BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival ComparisonsRuitao Lin, Peter F Thall, Ying Yuan
Pharmaceutical Statistics|January 24, 2017
A simulation study of methods for selecting subgroup-specific doses in phase 1 trialsSatoshi Morita, Peter F Thall, Kentaro Takeda
Pharmaceutical Statistics|July 19, 2022
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpointYun Qing, Peter F Thall, Ying Yuan
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|July 14, 2005
Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun, Zheng Yuan, Peter F Thall
Journal of the American Statistical Association|February 12, 2019
A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment RegimesThomas A Murray, Ying Yuan, Peter F Thall
Clinical Advances in Hematology & Oncology : H&O|June 2, 2006
Some ethical issues in phase II trials in acute leukemiaPeter F Thall, Elihu H Estey, Maurie Markman
The Annals of Applied Statistics|November 5, 2019
Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer PatientsJuhee Lee, Peter F Thall, Steven H Lin
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 13, 2012
Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknownYing Yuan, Peter F Thall, Johannes E Wolff
Pageof 19

Showing results (41-50 of 190) with videos related to

Sort By:
Pageof 19
Pharmaceutical Statistics|April 11, 2023
Generalized phase I-II designs to increase long term therapeutic success ratePeter F Thall, Yong Zang, Ying Yuan
Journal of the American Statistical Association|May 18, 2022
BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival ComparisonsRuitao Lin, Peter F Thall, Ying Yuan
Pharmaceutical Statistics|January 24, 2017
A simulation study of methods for selecting subgroup-specific doses in phase 1 trialsSatoshi Morita, Peter F Thall, Kentaro Takeda
Pharmaceutical Statistics|July 19, 2022
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpointYun Qing, Peter F Thall, Ying Yuan
Biometrics|August 17, 2022
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicityJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|July 14, 2005
Determining a maximum-tolerated schedule of a cytotoxic agentThomas M Braun, Zheng Yuan, Peter F Thall
Journal of the American Statistical Association|February 12, 2019
A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment RegimesThomas A Murray, Ying Yuan, Peter F Thall
Clinical Advances in Hematology & Oncology : H&O|June 2, 2006
Some ethical issues in phase II trials in acute leukemiaPeter F Thall, Elihu H Estey, Maurie Markman
The Annals of Applied Statistics|November 5, 2019
Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer PatientsJuhee Lee, Peter F Thall, Steven H Lin
Journal of the Royal Statistical Society. Series C, Applied Statistics|March 13, 2012
Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknownYing Yuan, Peter F Thall, Johannes E Wolff
Pageof 19